Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

North America: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector driven by Artificial Intelligence (LTM June 2022)

  • A total of 35 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of the North America region, driven by Artificial Intelligence, in the last twelve months resulting in a total deal value of over $1,990.6 million. In the LTM period, June 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $433.5 million, resulting in an average deal value of $72.3 million during that month. On the other hand, the month of July 2021 was the most prolific in terms of deal volume, recording a total of 6 deals, resulting in an average deal value of $39.5 million during that month.

  • Of the 35 deals, the deal secured between 5Y Capital; Orbimed Advisors LLC; RRJ Capital; Sequoia Capital Operations LLC; Sino Biopharmaceutical Ltd and XtalPi Inc, was the largest Private Equity/Venture Financing deal in the North America Pharmaceuticals sector driven by Artificial Intelligence, which was valued at $400.0 million and was completed on August 11, 2021. The second-largest deal was between B Capital Group Management, L.P.; Baidu Ventures; Bold Capital Partners; CITIC Industrial Investment Fund Management Co Ltd; Deerfield Management Co LP; Eight Roads Ventures; Formic Ventures; Lake Bleu Capital; Lilly Asia ventures; Maison Capital Group; Mirae Asset Capital Co Ltd; Orbimed Advisors LLC; Pavilion Capital Partners LLC; President International Development Corporation; Qiming Venture Partners; Sage Partners; Sequoia Capital China; Sinovation Ventures; Warburg Pincus LLC and InSilico Medicine, while the third-largest deal was between Ally Bridge Group; ARCH Venture Partners LP; ArrowMark Partners; Deep Track Capital LP; Great Point Ventures Fund; Illumina Ventures; Janus Henderson Investors; Logos Global Management LLC; Ono Venture Investment Inc; Piper Heartland Healthcare Capital, LLC; Ridgeback Capital Investment LLC; Section 32; Surveyor Capital Ltd; T Rowe Price Associates Inc; Tao Capital Partners; TCG Crossover; Tekla Capital Management LLC; Temasek Holdings (Private) Ltd; Vertex Pharmaceuticals Inc; Woodline Partners and Arbor Biotechnologies Inc. The B Capital Group Management, L.P.; Baidu Ventures; Bold Capital Partners; CITIC Industrial Investment Fund Management Co Ltd; Deerfield Management Co LP; Eight Roads Ventures; Formic Ventures; Lake Bleu Capital; Lilly Asia ventures; Maison Capital Group; Mirae Asset Capital Co Ltd; Orbimed Advisors LLC; Pavilion Capital Partners LLC; President International Development Corporation; Qiming Venture Partners; Sage Partners; Sequoia Capital China; Sinovation Ventures; Warburg Pincus LLC-InSilico Medicine deal and the Ally Bridge Group; ARCH Venture Partners LP; ArrowMark Partners; Deep Track Capital LP; Great Point Ventures Fund; Illumina Ventures; Janus Henderson Investors; Logos Global Management LLC; Ono Venture Investment Inc; Piper Heartland Healthcare Capital, LLC; Ridgeback Capital Investment LLC; Section 32; Surveyor Capital Ltd; T Rowe Price Associates Inc; Tao Capital Partners; TCG Crossover; Tekla Capital Management LLC; Temasek Holdings (Private) Ltd; Vertex Pharmaceuticals Inc; Woodline Partners-Arbor Biotechnologies Inc deal were valued at $255.0 million and $215.0 million, respectively. The fourth-largest deal was between Oaktree Capital Management LP; Qatar Investment Authority-BioXcel Therapeutics Inc valued at $125.0 million, whereas the deal between Boxer Capital LLC; GV Capital; Lightspeed Venture Partners - US; Polaris Partners LLC; Samsara BioCapital LLC; Timothy A. Springer-Seismic Therapeutic Inc valued at $101.0 million was the fifth-largest deal.

  • Cumulatively, the top five deals amounted to $1,096.0 million and accounted for nearly 55.06% of the total deals (by value) announced during the last twelve months. The North America region accounted for 80.66% of the total Private Equity/Venture Financing deals done globally, and accounted for 64.81% of the total deal size on a global scale.

North America: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector driven by Artificial Intelligence (LTM June 2022)

Published: June 2022
Source: GlobalData



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward